Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Gilead Sciences, Inc. (GILD), Johnson & Johnson (JNJ): Is a Breakthrough Treatment on the Way for People With HIV?

Page 1 of 2

We as a country have a come a long way over the past two decades with regard to treating HIV and reducing the number of AIDS diagnoses. Plenty of factors have contributed to this reduction including better education of the public about the risk factors, as well as improved medication.

Gilead is cleaning up
At the head of the pack in slowing the progression of HIV in patients who have tested positive is Gilead Sciences, Inc. (NASDAQ:GILD). You could certainly say that Gilead Sciences, Inc. (NASDAQ:GILD) has done its part to corner the market on HIV medications, introducing Truvada with an approval by the Food and Drug Administration in 2012 for patients at high risk of acquiring HIV through sexual activity.

Gilead Sciences, Inc. (NASDAQ:GILD)

However, in 2006, long before Truvada, Gilead Sciences, Inc. (NASDAQ:GILD) introduced its three-in-one once-daily HIV treatment known as Atripla. Aside from being a landmark once-daily pill, which meant greater ease of use for patients, it also was a rarity in that it marked the collaboration of three behemoth biopharmaceutical providers to develop a drug for a serious disease. Atripla combined three drugs — one from Gilead, one from Bristol Myers Squibb Co. (NYSE:BMY), and one from Johnson & Johnson (NYSE:JNJ) — which resulted in nearly $3.6 billion in total revenue last year.

Gilead hasn’t stopped there, either. In August, Gilead Sciences, Inc. (NASDAQ:GILD) launched its latest and greatest HIV-suppressing treatment known as Stribild. Using a combination of four separate drugs in a once-daily pill, over a 48-week period Stribild delivered undetectable levels of HIV in 88% to 90% of patients in late-stage trials. By comparison, Atripla and Truvada in combination with atazanavir and ritonavir provided undetectable HIV levels in 84% and 87% of patients over the same time period, respectively. Stribild sales totaled $92 million in the first quarter, up about 130% over the sequential quarter, and is certainly shaping up to be a blockbuster. Even more impressively for Gilead Sciences, Inc. (NASDAQ:GILD), Stribild is based on four drugs developed entirely in house which means no revenue sharing with Bristol Myers Squibb Co. (NYSE:BMY) or Johnson & Johnson (NYSE:JNJ).

Is new hope on the horizon for HIV patients?
As you might expect, with Stribild expected to slowly erode sales for Atripla and Truvada over time, Gilead Sciences, Inc. (NASDAQ:GILD)’s peers have been looking for new ways to stick their nose in the HIV revenue treatment pipeline. Surprisingly, we may be seeing the next real advance in the treatment of HIV come from a company not named Gilead Sciences.

Page 1 of 2

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!